Vicapsys Life Sciences, Inc.
Vicapsys focuses on leveraging natural pathways in a localized manner to achieve therapeutic benefits without systemic negative consequences. Their core technology is a pleiotropic cytokine, CXCL12, formulated for various indications. The company is currently focused on curing Type 1 diabetes through long-term survival of transplanted islet cells. They also address the consequences of diabetes and localized fibrosis.
Offizielles Register
KI-Qualitätsanalyse
Vertrauensscore-Details
Schnellzugriff
Website-Highlights
🌟 Ähnliche vertrauenswürdige Unternehmen
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Sigyn Therapeutics, Inc.
Sigyn Therapeutics develops dialysis-like therapies for cardiovascular disease and cancer. Their therapies are designed to improve patient quality of life. Key products include CardioDialysis™ for cardiovascular disease, and ImmunePrep™, ChemoPrep™ and ChemoPure™ for cancer therapy.